A second cut-price biosimilar of Amgen’s Neulasta (pegfilgrastim) long-acting white blood cell booster is to hit the EU market after the European Commission approved Mundipharma’s Pelmeg.
Gene and cell therapy firm Oxford Biomedica is to invest £4 million to build digital and robotics capabilities that will help manufacture the next generation of cutting edge therapies.
Johnson & Johnson’s share price took a beating this week after the US appeals court declined its bid to stop sales of cheap generic versions of its blockbuster prostate cancer drug Zyti
Australia continues to show the world how not to implement an electronic health records system, after health minister Greg Hunt has extended the deadline for opting out of the country’s con
